Fibrinolysin or agents that convert plasminogen to fibrinolysin.
1
However, the impact of diabetes on survival in patients treated with fibrinolytic agents is still undefined.
2
Attempts to improve thrombolytic treatment include the search for better fibrinolytic agents and more effective adjunctive therapies.
3
The latter might in part be explained by increasing use concomitant antiplatelet therapy, pre-hospital treatment and fibrin-specific fibrinolytic agents.
4
Conclusions: A history of diabetes is associated with a worse prognosis after myocardial infarction, even in patients treated with fibrinolytic agents.
5
Methods: We analyzed prevalence and prognostic significance of a history of diabetes in patients enrolled in the GISSI-2 study, all of whom received fibrinolytic agents.
1
These findings indicated that AnxB1ScuPA might have advantages over current available thrombolytic agents.
2
However, thrombolytic agents have limited effectiveness and are associated with a significant risk of bleeding.
3
The newer-generation thrombolytic agents remain of limited efficacy in the treatment and prevention of shock.
4
Twelve randomized, controlled trials of thrombolytic agents in 611 UA patients with predefined clinical endpoints have been published.
5
This meta-analysis showed that thrombolytic agents significantly improved the rate of return of spontaneous circulation, 24 h surviva …
1
However, the impact of diabetes on survival in patients treated with fibrinolytic agents is still undefined.
2
Attempts to improve thrombolytic treatment include the search for better fibrinolytic agents and more effective adjunctive therapies.
3
The latter might in part be explained by increasing use concomitant antiplatelet therapy, pre-hospital treatment and fibrin-specific fibrinolytic agents.
4
Conclusions: A history of diabetes is associated with a worse prognosis after myocardial infarction, even in patients treated with fibrinolytic agents.
5
Methods: We analyzed prevalence and prognostic significance of a history of diabetes in patients enrolled in the GISSI-2 study, all of whom received fibrinolytic agents.
1
Current methods for enzymatic activity of thrombolytic drugs are costly and complex.
2
Its efficacy is comparable to that of other available thrombolytic drugs.
3
Early treatment with thrombolytic drugs has been shown to reduce mortality in patients with acute myocardial infarction.
4
Thrombolytic drugs (rt-PA followed by Streptokinase) were injected via the same filter catheter.